Sign in
CompletedNo phase

Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions

Key facts

Who runs it
Imperial College London
Where
United Kingdom4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
40 people enrolled
Started
1 Jul 2021
Ended
1 Apr 2024
Type of study
Observational
Record updated
18 April 2024

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Evidence of SARS-CoV-2 PCR/Seropositive
  • Presence of interstitial lung disease on CT
  • Participant is willing and able to give informed consent for participation in the study
  • Aged 18 years or above

Who cannot take part

  • Confirmed ILD diagnosis prior to March 2020
  • Use of steroids at baseline visit
  • Patients with co-morbid disease that in the opinion of the investigators gives them an expected life expectancy of less than one year will be excluded from the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
POST COvid-19 Interstitial Lung DiseasE (POSTCODE) A Study of Genetic and Environmental Interactions: an Observational Cohort Study.
Record updated
18 April 2024